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Background: Randomised controlled trials (RCTs) of adjunctive vitamin D in pulmonary 
tuberculosis (PTB) treatment have yielded conflicting results. Individual participant data 
(IPD) meta-analysis could identify factors explaining this variation. 
Methods: We meta-analyzed IPD from RCTs of vitamin D in patients receiving 
antimicrobial therapy for PTB. Primary outcome was time to sputum culture conversion. 
Secondary outcomes were time to sputum smear conversion, mean 8-week weight and 
incidence of adverse events. Pre-specified sub-group analyses were done according to 
baseline vitamin D status, age, sex, drug-susceptibility, HIV status, extent of disease, 
and vitamin D receptor genotype. 
Results: IPD were obtained for 1,850 participants in 8 studies. Vitamin D did not 
influence time to sputum culture conversion overall (aHR 1.06, 95% CI 0.91-1.23), but it 
did accelerate sputum culture conversion in participants with multidrug-resistant PTB 
(aHR 13.44, 95% CI 2.96-60.90); no such effect was seen in those whose isolate was 
sensitive to rifampicin and/or isoniazid (aHR 1.02, 95% CI 0.88-1.19; Pinteraction =0.02). 
Vitamin D accelerated sputum smear conversion overall (aHR 1.15, 95% CI 1.01-1.31), 
but did not influence other secondary outcomes. 
Conclusions: Vitamin D did not influence time to sputum culture conversion overall, but 
it accelerated sputum culture conversion in patients with multidrug-resistant PTB. 
  
INTRODUCTION 
The World Health Organisation estimates that 10.0 million people developed active 
tuberculosis in 2017, and that 1.6 million people died of this disease.  1 Existing 
antimicrobial treatment for active tuberculosis requires lengthy administration of a 
high pill burden that carries a significant risk of toxicity and has limited efficacy in 
drug-resistant disease. Adjunctive host-directed therapies (i.e. immunomodulatory 
therapies given in addition to antimicrobial treatment) have the potential to reduce 
duration of transmissibility, shorten antimicrobial therapy and improve outcomes in 
drug-resistant disease.2 Vitamin D has attracted interest as a potential candidate on the 
basis of its historical use in tuberculosis treatment,3 reported associations between 
vitamin D deficiency and susceptibility to tuberculosis infection and disease,4,5 and its 
recognized role in supporting antimycobacterial immune responses.6,7 Double-blind 
randomized placebo-controlled trials evaluating effects of vitamin D supplementation on 
sputum culture and/or smear conversion in patients receiving antimicrobial therapy for 
pulmonary tuberculosis have yielded conflicting results: four report favorable effects on 
their primary outcome in the study population as a whole,8-11 two report benefits on their 
primary outcome in sub-groups only,12,13 and four report no effects of the intervention on 
their primary outcome.14-17  Systematic reviews and aggregate data meta-analyses 
including at least some of these studies18-21 are all limited by lack of access to individual 
participant data, which precludes conduct of sub-group analyses to explore whether 
individual-level factors may modify responses to vitamin D supplementation. This is an 
important omission, because uneven distribution of such effect-modifiers between 
participants in different settings might underlie variation in results seen between trials. 
For example, effects of vitamin D supplementation may be modified by drug-
susceptibility of a patient’s Mycobacterium tuberculosis isolate: this might be expected 
on the grounds that individuals with drug-resistant disease may stand to derive 
particular benefit from host-directed therapy where antimicrobial therapies are less 
effective.2 Alternatively, effects of vitamin D supplementation may be stronger in, or 
restricted to, individuals with lower baseline vitamin D status, since these individuals 
might be expected to derive the greatest benefit from vitamin D replacement. This 
phenomenon has been demonstrated in other respiratory diseases.22-24 We therefore 
set out to obtain individual participant data from the ten clinical trials listed above and 
meta-analyze them in order to obtain an updated estimate of overall efficacy, and to 
determine whether effects of this intervention vary according to the presence or 









Protocol and Registration 
The methods for this systematic review and meta-analysis were described in an outline 
protocol that was registered with the PROSPERO International Prospective Register of 
Systematic Reviews, number CRD42015020288 
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015020288 ). 
Research ethics committee approval to contribute individual participant data from 
completed primary trials to the current meta-analysis was not required for any study. 
Findings are reported according to the PRISMA guidelines for individual participant data 
meta-analysis.25 
 
Selection of studies and participants 
Double-blind, placebo-controlled randomized controlled trials of adjunctive vitamin D 
supplementation including patients receiving standard antimicrobial treatment for 
pulmonary tuberculosis were eligible for inclusion if the primary trial had been approved 
by a Research Ethics Committee, and if data on sputum culture and/or smear 
conversion were reported. Studies in which vitamin D was given in combination with 
another intervention were excluded if effects of vitamin D could not be isolated (e.g. by 
use of a factorial design). Studies in which a factorial design was used to investigate 
effects of other therapies alongside vitamin D were included, as these allowed effects of 




 Individual participants in eligible studies were excluded if pulmonary tuberculosis was 
not confirmed by sputum culture or smear, i.e. we only included data from individual 
patients in the meta-analysis if they had either a positive sputum smear at baseline or a 
positive sputum culture at baseline or both. 
 
Data Sources and Searches 
Two investigators (DAJ and ARM) searched PubMed, EMBASE, the Cochrane Central 
Register of Controlled Trials (CENTRAL) and Web of Science using the electronic 
search strategies described in the Appendix. Searches were regularly updated up to 
and including 10th November 2017. No language restrictions were imposed. Two 
investigators (DAJ and ARM) determined which studies met the eligibility criteria. 
 
Data Extraction and Quality Assurance 
Individual participant data were requested from the Principal Investigator for each 
eligible trial, and the terms of collaboration were specified in a data transfer agreement, 
signed by representatives of the data provider and the recipient (Queen Mary University 
of London). Data were de-identified at source prior to transfer via email. On receipt, two 
investigators (DAJ and ARM) assessed data integrity by performing internal consistency 
checks and by cross-checking proportions of participants with positive 8-week sputum 
culture and smear by arm against those reported in published papers. Study authors 
were contacted to provide missing data and to resolve queries arising from these 
integrity checks. Once queries had been resolved, clean data were uploaded to the 
main study database, which was held in STATA IC v12 (College Station, TX, USA).  
 
The following data relating to study characteristics were collected: study setting, 
eligibility criteria, details of adjunctive therapies being evaluated in each trial and 
duration of follow-up. Individual participant data were extracted for the following 
variables relating to baseline characteristics: age, sex, weight, circulating 25(OH)D 
concentration, drug susceptibility, human immunodeficiency virus (HIV) status, extent of 
disease on baseline chest radiograph (as measured by the proportion of zones involved 
and the presence or absence of cavitation), genotype for single nucleotide 
polymorphisms (SNPs) in the gene encoding the vitamin D receptor (VDR, FokI and 
TaqI), and study allocation (vitamin D vs placebo). Follow-up data were requested for 
time from initiation of antibiotic treatment to stable sputum culture/smear conversion 
(the date of stable culture/smear conversion being estimated as the midpoint between 
the date of the last positive sputum culture/smear and the date of the first negative 
sputum culture/smear thereafter); sputum culture and smear status, weight and 
circulating 25(OH)D concentration after 8 weeks of antimicrobial treatment; and 
occurrence of serious adverse events, death, study withdrawals, and potential adverse 
reactions to vitamin D supplementation (hypercalcemia or renal stones). 
 
Risk of Bias Assessment for Individual Studies 
We used the Cochrane Collaboration Risk of Bias tool26 to assess the following 
variables: sequence generation, allocation concealment, blinding of participants, 
personnel and outcome assessors, completeness of outcome data, evidence of 
selective outcome reporting and other potential threats to validity. Selectivity of reporting 
was assessed either by comparing study protocols against study reports, or by 
specifically asking study authors whether all pre-specified outcomes were reported. 
Study quality was assessed independently by two investigators (ARM and DAJ), except 
for the trials in which ARM was an investigator,12,13 which were assessed by RR and 
MAH. Discrepancies were resolved by consensus. 
 
Definition of Outcomes 
The primary outcome of the meta-analysis was time from initiation of antimicrobial 
therapy to stable sputum culture conversion, estimated as the midpoint between the last 
positive sputum culture and the first negative sputum culture thereafter. This outcome 
was selected as primary because it is a recognized surrogate for treatment failure and 
relapse that reflects the longitudinal profile of culture results over time, as opposed to a 
single time point.27 Participants who were unable to expectorate spontaneously at 
follow-up time points were deemed to be culture negative. Where participants were 
culture positive at 8-week follow-up (or earlier if lost to follow-up before this time point), 
time to sputum culture conversion was attributed as the number of days from the date of 
treatment initiation to the date of the last follow-up visit, and the censor variable was 
assigned a zero value to indicate that the endpoint of sputum culture conversion was 
not achieved. Secondary outcomes were time to stable sputum smear conversion, 
estimated as the midpoint between the last positive sputum smear and the first negative 
sputum smear thereafter; proportions of participants with negative sputum culture / 
smear after 8 weeks of antimicrobial therapy; weight after 8 weeks of antimicrobial 
therapy; and risk of death, study withdrawals, and potential adverse reactions to vitamin 
D supplementation (hypercalcemia or renal stones). Time to sputum culture / smear 
conversion was estimated only for trials where sputum was collected at intervals of two 
weeks or less, due to the potential for imprecision of such an estimate with less frequent 
sputum collection. 
 
Data Synthesis and Analysis 
DAJ and ARM analyzed the data using STATA IC, version 12. Our individual participant 
data meta-analysis approach followed published guidelines.28 We did both one-step and 
two-step individual participant data meta-analyses for the primary outcome of time to 
sputum culture conversion. For secondary outcomes, we did one-step individual 
participant data meta-analysis only. In the one-step approach, individual participant data 
from all studies were modelled simultaneously while accounting for the clustering of 
participants within studies. We used mixed models, with a random effect for study and 
fixed effects for age and sex (reflecting an assumption that the influence of age and sex 
on response to treatment would not vary across trials) to obtain the pooled intervention 
effect with a 95% CI. We did not adjust for other covariates because missing values for 
some participants would have led to their exclusion from statistical analyses. We 
analyzed survival data using mixed-effects parametric survival models; effects of the 
intervention on time to sputum culture/smear conversion were expressed as adjusted 
hazard ratios (aHRs). Survival data for time to sputum culture and smear conversion 
were truncated at 8 weeks in order to capture effects of adjunctive vitamin D on the 
standardized background of intensive-phase antimicrobial therapy. We analyzed 
proportions of participants experiencing an event using mixed-effects logistic 
regression; effects of the intervention on dichotomous outcomes were expressed as 
adjusted odds ratios (aORs). In the two-step approach, individual participant data were 
first analyzed for each separate study independently to produce a hazard ratio for the 
effect of allocation on time to sputum culture conversion for that study, adjusted for age 
and sex. We then calculated a weighted average of adjusted hazard ratios for each 
study and summarized heterogeneity using the I2 statistic.  
 
Exploration of Variation in Effects 
To identify factors modifying the effects of vitamin D supplementation, we did pre-
specified subgroup analyses for the primary outcome of time to sputum culture 
conversion by extending the one-step meta-analysis framework to include treatment-
covariate interaction terms. Subgroups were defined according to baseline vitamin D 
status (circulating 25[OH]D concentration <25 vs ≥25 nmol/L), age (< vs ≥ the median 
value of 30 years), sex, drug susceptibility (multidrug-resistant [i.e. resistant to at least 
rifampicin and isoniazid] vs not), HIV status (seronegative vs seropositive), extent of 
chest radiograph involvement at baseline (<50% vs ≥50% of zones involved and 
presence vs absence of cavitation), vitamin D dosing regimen (daily/weekly vs less 
frequently), and VDR genotype for the FokI and TaqI SNPs (analyzed using the per-
allele method i.e. under an additive model). The 25 nmol/L cut-off for baseline 25(OH)D 
concentration in the subgroup analyses was selected because it is the threshold for 
vitamin D deficiency defined by the UK Department of Health,29 and because we have 
previously shown this threshold to modify host response to respiratory infection.22 The 
Benjamini–Hochberg procedure for multiple testing correction was applied to the family 
of P values for interaction to control the false discovery rate (FDR) at 20%. 
 
Risk of Bias Assessment Across Studies 
For the primary analysis, the likelihood of publication bias was investigated through the 
construction of a contour-enhanced funnel plot. 
 
Additional analyses 
We did a pre-specified responder analysis in participants assigned to the intervention 
arm of included studies, comparing time to sputum culture conversion in participants 
who attained a circulating 25(OH)D concentration of 75 nmol/L or higher vs those who 
did not. We did two exploratory adjustments of the sub-group analysis evaluating effects 
of vitamin D in patients with vs. without MDR-TB, controlling for baseline vitamin D 
status (25[OH]D <25 nmol/L vs. ≥25 nmol/L) and presence vs. absence of cavitation on 
baseline chest radiograph in addition to the pre-specified adjustments for age, sex and 
clustering of participants within trials. A pre-specified sensitivity analysis excluding 
studies deemed at high risk of bias was not conducted, since no included trial fell into 





Study Selection and Individual Participant Data Obtained 
The study selection process is illustrated in Figure 1. Our search identified 513 unique 
studies that were assessed for eligibility, of which 10 studies with a total of 2,223 
randomized participants fulfilled eligibility criteria. Individual participant data were sought 
for all studies, and obtained for 8/10 studies (total 2,096 participants). Individual 
participant data were not obtained for 2 studies (total of 127 participants): in one case 
the corresponding author indicated that individual participant data were not available,8 
and in the other, the corresponding author did not respond to an invitation to contribute 
individual participant data to this meta-analysis.11 A total of 246 randomized participants 
in the 8 studies for which individual participant data were obtained were excluded from 
the meta-analysis on the grounds that they did not have pulmonary tuberculosis 
confirmed by sputum culture and/or smear. All of the remaining 1,850 participants 
contributed data to analysis of serious adverse events; 1,163 participants contributed 
data to analysis of sputum culture conversion, and 1,611 participants contributed data to 
analysis of sputum smear conversion. Differences in the total number of participants 
contributing to these analyses represent differences in data availability: serious adverse 
event data were available for all, but microbiological outcome data were not.  
 
Study and Participant Characteristics 
The eight studies for which individual participant data were obtained were conducted in 
eight countries on three continents (Table 1). All studies investigated effects of vitamin 
D3; none investigated vitamin D2. Six studies used two-arm parallel designs to 
investigate effects of vitamin D3 only; 
9,12-14,16,17 two studies investigated effects of other 
host-directed therapies concurrently using a factorial design.10,15 Seven studies 
administered vitamin D3 orally to participants in the intervention arm: this was given 
daily,10 weekly then 2-weekly,17 2-weekly,12,13,16 4-weekly,15 and three times over an 8-
month period (at baseline, 5 months and 8 months).14 One study administered vitamin 
D3 intramuscularly to participants in the intervention arm at baseline and 4 weeks.
9 
Duration of follow-up ranged from 8 weeks to 8 months. Primary outcomes included one 
or more of sputum culture conversion,10,12,13,15-17 clinical scores,10,14,15 weight gain9 and 
end-study chest radiograph involvement.9 Data relating to final treatment outcome were 
available for 331 participants in two trials14,15 (Appendix Table 1). The 1,850 participants 
included in individual participant data meta-analysis ranged in age from 15 to 86 years, 
and 650 (35.1%) were female. Baseline HIV status was tested in 995 participants in 5 
studies,12,14-17 and found to be positive in 157 (15.8%) of them. Baseline 25(OH)D 
concentrations were determined in 1,660 participants in 6 studies, 10,12-14,16,17 and 
ranged from undetectable to 250 nmol/L: 688 participants tested (41.5%) had baseline 
25(OH)D levels <25 nmol/L. Drug susceptibility testing results were available for 1,350 
participants in 6 studies: 55 participants tested (4.1%) had multidrug-resistant 
tuberculosis (i.e. their M. tuberculosis complex isolate was resistant to isoniazid and 
rifampicin at least), of whom 39 (70.9%) commenced second-line anti-TB therapy during 
their participation in the trials; relatively early initiation of second-line therapy was made 
possible by the use of molecular methods in some studies that enabled the rapid 
detection of mutations associated with drug-resistance. Baseline characteristics of 
participants were comparable between study arms for the study population as a whole 
(n=927 allocated to vitamin D vs n=923 allocated to placebo; Appendix Table 2) and for 
the sub-group of participants with multidrug-resistant tuberculosis (n=30 allocated to 
vitamin D vs n=25 allocated to placebo; Appendix Table 3).  All studies included sputum 
smear conversion as an outcome measure; six studies additionally included sputum 
culture conversion as an outcome measure.10,12,13,15-17 Individual participant data 
integrity checks did not reveal any discrepancies between primary reports vs individual 
participant data supplied. 
 
Risk of Bias within Studies 
Details of the risk of bias assessment are provided in Appendix Table 4. Four trials were 
assessed as being at unclear risk of bias due to the relatively high proportion (>20%) of 
participants who were lost to follow-up.10,14-16  
 
Overall effect, primary outcome 
Overall, vitamin D supplementation did not have a statistically significant effect on the 
primary outcome of time to sputum culture conversion after initiation of antimicrobial 
therapy, either in one-step analysis (adjusted hazard ratio [aHR] 1.06, 95% CI 0.91 to 
1.23, P=0.44; 820 participants in 4 studies;12,13,16,17 Figure 2A) or in two-step analysis 
(aHR 1.06, 95% CI 0.91 to 1.23, P=0.46; P for heterogeneity =0.84; 820 participants in 4 
studies;12,13,16,17 Figure 3).  
 
 
Sub-group analyses, primary outcome 
Sub-group analyses were conducted using one-step individual participant data meta-
analysis to investigate whether effects of adjunctive vitamin D supplementation on time 
to sputum culture conversion differed according to baseline vitamin D status, age, sex, 
drug susceptibility, HIV status, extent of disease on baseline chest radiograph, 
presence or absence of cavitation on baseline chest radiograph, type of dosing regimen 
and VDR genotype. Results are presented in Table 2. Vitamin D supplementation 
accelerated sputum culture conversion among individuals with multi-drug resistant 
pulmonary tuberculosis (aHR 13.44, 95% CI 2.96 to 60.90; 37 participants in 4 studies; 
12,13,16,17 within sub-group P=0.001) but not in those whose isolate was sensitive to 
rifampicin and/or isoniazid (aHR 1.02, 95% CI 0.88 to 1.19; 780 participants in 4 
studies;12,13,16,17 within sub-group P=0.32; P for interaction =0.02). The P value for 
interaction for this sub-group analysis remained significant after correction for multiple 
comparisons testing, using the Benjamini and Hochberg method with a false discovery 
rate of 20%. Because we noted a degree of imbalance in the proportion of patients with 
MDR TB who had cavitation in intervention vs. control arms (26.7% vs. 48.0% 
respectively, Appendix Table 3) we conducted an exploratory sub-group analysis 
additionally controlling for presence vs. absence of cavitation. Results of the subgroup 
analysis were not materially affected (within-subgroup aHR for patients with MDR TB 
11.43, 95% CI 2.22 to 58.94; 36 participants in 3 studies;12,13,17 within sub-group 
P=0.004; P for interaction = 0.03). We also noted that the prevalence of baseline 
vitamin D deficiency was higher in participants with vs. without MDR TB (61.8% vs. 
41.4% respectively, P=0.003). However, results of the sub-group analysis were not 
materially affected when additional adjustment was made for the presence vs. the 
absence of vitamin D deficiency at baseline (P for interaction =0.02). P values for 
interaction for all other sub-group analyses were greater than 0.05.  
 
Secondary outcomes, efficacy 
Adjunctive vitamin D accelerated sputum smear conversion (median time to sputum 
smear conversion, 21 days for vitamin D vs. 26 days for placebo; aHR 1.15, 95% CI 
1.01, 1.31, P=0.03; 1,200 participants in 6 studies;10,12-16 Figure 2B). However, the 
proportion of participants with negative sputum culture and smear at 8 weeks was not 
significantly different for those randomized to vitamin D vs placebo (490/577 [84.9%] vs 
484/586 [82.6%] culture negative at 8 weeks, aOR 1.17, 95% CI 0.85 to 1.60, P=0.33, 
1,163 participants in 6 studies;10,12,13,15-17 644/806 [79.9%] vs 608/805 [75.5%] smear 
negative at 8 weeks, aOR 1.29, 95% CI 1.00 to 1.67, P=0.051; 1,611 participants in 8 
studies). 9,10,12-17 Administration of adjunctive vitamin D did not influence mean weight 
after 8 weeks of antimicrobial therapy in participants randomized to vitamin D vs 
placebo (53.2 vs 53.4 kg, respectively; mean difference 0.13 kg, 95% CI -0.24 to 0.49 
kg, P=0.43; 1,634 participants in 8 studies).9,10,12-17 
 
Secondary outcomes, safety 
Results of one-step individual participant data meta-analysis of safety outcomes are 
reported in Appendix Table 5. No participant experienced renal stones. There was no 
difference in the proportion of participants allocated to vitamin D vs. placebo 
experiencing hypercalcemia (6.2% vs. 6.1%, P=0.83), serious adverse events of any 
cause (3.6% vs. 3.5%, P=0.96), study withdrawal (12.6% vs. 13.4%, P=0.79) or death 
due to any cause (2.5% vs. 2.3%, P=0.79). 
 
Risk of Bias Across Studies 
A funnel plot for the outcome of time to sputum culture conversion did not suggest 
publication bias in relation to this outcome, since randomized controlled trials showed 




Results of responder analysis are presented in Appendix Table 6. Among participants 
randomized to the intervention arm of studies for which end-study 25(OH)D data were 
available, no difference in time to sputum culture conversion was observed between 





We report results of the first meta-analysis of individual participant data from 
randomized controlled trials of adjunctive vitamin D in patients with pulmonary 
tuberculosis. In the study population as a whole, vitamin D supplementation did not 
influence the primary outcome of time to sputum culture conversion, but it did modestly 
accelerate sputum smear conversion, which was a secondary outcome. Pre-specified 
sub-group analysis revealed that vitamin D accelerated sputum culture conversion in 
participants with multidrug-resistant pulmonary tuberculosis, but not in those whose 
mycobacterial isolate was sensitive to rifampicin or isoniazid or both. Vitamin D 
supplementation was safe at the doses administered: no instances of renal stones were 
seen, and serious adverse events were evenly distributed between participants 
randomized to vitamin D vs placebo. 
 
Our overall finding of no effect of vitamin D on time to sputum culture conversion is 
consistent with results from existing systematic reviews and aggregate data meta-
analyses, although our findings of accelerated sputum smear conversion are at variance 
with them.18-21 In contrast to the lack of effect overall, the favorable effect of vitamin D 
on time to culture conversion that we demonstrate in the sub-group of patients with 
multidrug-resistant tuberculosis is of potential clinical significance. Moreover, it is 
biologically plausible, since host-directed therapies such as vitamin D are likely to 
confer greater benefit in scenarios where antimicrobial therapy is less effective.2 
Caution in interpreting results of this sub-group analysis is warranted for several 
reasons. First, a significant minority (29.1%) of participants with MDR TB did not receive 
any second-line antimicrobial therapy during their participation in the trials; thus, 
findings cannot be generalized to patients receiving optimal antimicrobial treatment for 
MDR TB. Second, the analysis is based on a relatively small number of participants – 
accordingly the 95% CI for the adjusted hazard ratio is wide. Third, the potential for a 
positive result arising by chance as a consequence of several sub-group analyses being 
conducted cannot be discounted. However, we minimized the potential for type 1 error 
by pre-specifying a limited number of sub-group analyses, each of which was supported 
by an independent hypothesis; the P value for interaction for this sub-group analysis 
(0.02) remained significant after correction for multiple comparisons testing. All in all, 
when taken together with data from observational studies showing that low 25(OH)D 
associates with delayed sputum smear conversion in patients receiving second-line 
therapy for multidrug-resistant pulmonary tuberculosis,30 and considering the low cost 
and low toxicity of adjunctive vitamin D supplementation, the positive finding in this sub-
group provides a rationale for conducting a new randomized controlled trial to 
investigate effects of this intervention in patients receiving second-line antimicrobial 
therapy for multidrug-resistant tuberculosis. However, in our judgement, the strength of 
evidence from this sub-group analysis is not sufficient to justify a clinical 
recommendation to use of adjunctive vitamin D in the treatment of MDR TB without 




Strengths and limitations of this study 
Our study has several strengths. It is unique in that we had access to individual 
participant data: this allowed us to conduct sub-group analyses to determine whether 
effects of vitamin D supplementation varied between individuals. We included data from 
eight out of ten eligible studies (88% of participants worldwide), none of which were 
assessed as being at high risk of bias, and restricted analysis to patients who had 
microbiologically confirmed tuberculosis. Included studies recruited patients from low- 
and high-incidence settings in three continents, enhancing generalizability of our results. 
Our primary outcome of time to sputum culture conversion is accepted as the preferred 
endpoint for phase II trials of new TB regimens.27 Our definition captured stable culture 
conversion only, i.e. if a patient became culture negative but subsequently reverted to 
culture positive, this was not classified as sputum culture conversion. 
 
Our study also has some limitations. We failed to obtain individual participant data from 
2/10 eligible trials.8,11 However, neither of these studies investigated our primary 
outcome of sputum culture conversion, and both were small (n=67 and n=60): their 
omission therefore has a limited impact on secondary outcomes only. Of note, both 
trials reported favorable effects of vitamin D on their primary outcome: therefore, if their 
omission does introduce a bias, that bias would likely be towards the null. Interpretation 
of the Funnel plot (Appendix Figure 1) is limited by the small number of studies 
included, but the fact that the smaller randomized controlled trials showed an equal 
spread of results on both sides of the overall adjusted hazard ratio provides some 
reassurance that publication bias was not a major issue in our meta-analysis. A further 
limitation is that end-of-treatment outcomes were not available for meta-analysis: this 
reflects that fact that almost all trials had relatively short follow-up. However, in the 
absence of a consistent signal from the phase 2B studies included in this meta-analysis, 
phase 3 trials of adjunctive vitamin D with end-of-treatment outcomes are not likely to 
be conducted. Our meta-analysis therefore represents the best evidence in this field 
that is likely to become available. 
 
Conclusions and policy implications 
In conclusion, we show that adjunctive vitamin D does not influence time to sputum 
culture conversion in drug-sensitive pulmonary tuberculosis, but it may accelerate 
sputum culture conversion in patients with multidrug-resistant disease. Randomized 
controlled trials of vitamin D supplementation in patients with multidrug-resistant 
pulmonary tuberculosis are therefore justified.  
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performed, since vitamin D2 was not administered in any included study: all investigated 
vitamin D3. A pre-specified sensitivity analysis excluding studies deemed at high risk of 
bias was not conducted, since no included trial fell into this category. In response to 
reviewers’ requests we did two exploratory adjustments of the sub-group analysis 
evaluating effects of vitamin D in patients with vs. without MDR-TB in addition to the 
pre-specified adjustments for age, sex and clustering of participants within trials: one 
included additional adjustment for baseline vitamin D status (25[OH]D <25 nmol/L vs. 
≥25 nmol/L) and the other included additional adjustment for presence vs. absence of 
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1. Where denominators are less than total number of included participants, data are missing  
2. 126 excluded (113 smear negative at baseline, 11 extra-pulmonary tuberculosis only, 2 with final diagnosis other than tuberculosis) 
3. 11 excluded (8 cultured non-tuberculous mycobacteria, 3 culture negative at baseline) 
4. 36 excluded (19 culture negative at baseline, 13 culture missing at baseline, 4 culture contaminated at baseline) 
5. 28 excluded (all culture negative at baseline)  
6. 38 excluded (37 culture negative at baseline, 1 culture missing at baseline) 
7. 7 excluded (all culture negative at baseline) 
 
40,000 international units (IU) vitamin D3 = 1 mg; 25(OH)D concentrations reported in ng/ml were converted to nmol/L by multiplying by 2.496. 25(OH)D, 25-
hydroxyvitamin D; N/A, not applicable; LC-MS/MS, liquid chromatography tandem-mass spectrometry; ECLIA, electrochemiluminescence immunoassay; CLIA, 
chemiluminescence immunoassay; MDR TB, multidrug-resistant tuberculosis, i.e. resistant to isoniazid and rifampicin at least; PBA, 4-phenylbutyrate; H, isoniazid; R, 
rifampicin; Z, pyrazinamide; E, ethambutol.
 
Table 2: One-step individual participant data meta-analysis, time to sputum culture conversion after 










Median time to 
sputum culture 
conversion, 






P value P value for 
Interaction 
Overall 820 (4) 35 (21, 49) 35 (21, 49) 1.06 (0.91, 1.23) 0.44  
Baseline 25(OH)D 
concentration      
 
<25 nmol/L 480 (4) 35 (22, 49) 35 (21, 49) 1.14 (0.93, 1.40) 0.20 
0.25 
≥25 nmol/L 330 (4) 31 (20, 44) 34 (19, 46) 0.94 (0.75, 1.19) 0.62 
Age       
<30 years  350 (4) 35 (21, 49) 34 (20, 45) 1.09 (0.87, 1.37) 0.45 
0.70 
≥30 years 470 (4) 35 (23, 49) 35 (22, 49) 1.04 (0.85, 1.27) 0.74 
Sex       
Male 559 (4) 35 (22, 49) 35 (21, 49) 1.10 (0.91, 1.32) 0.32 
0.53 




      
 




Yes 37 (4) >56 (50, >56)
(3)





HIV status       
Seronegative 383 (3) 29 (20, 43) 29 (16, 41) 1.03 (0.84, 1.28) 0.75 
0.53 
Seropositive 8 (2) 21 (9, 36) 39 (10, 49) 0.09 (0.01, 0.89) 0.04 
% zones involved, baseline 
CXR      
 






≥50% 132 (2) 37 (28, 49) 36 (33, 50) 1.05 (0.70, 1.58) 0.82 
Cavitation, baseline CXR       
No 380 (3) 35 (21, 49) 35 (21, 45) 1.13 (0.90, 1.42) 0.29 
0.60 
Yes 294 (3) 36 (22, 50) 35 (21, 51) 1.03 (0.79, 1.34) 0.83 
Vitamin D Dosing Regimen        






Bolus/2-weekly 655 (3) 35 (21, 49) 35 (21, 49) 1.08 (0.91, 1.28) 0.39 
FokI VDR genotype       
FF 226 (2) 36 (23, 50) 35 (21, 51) 0.99 (0.73, 1.35) 0.97 
0.81 Ff 221 (2) 36 (21, 50) 35 (34, 49) 1.20 (0.88, 1.64) 0.24 
ff 56 (2) 36 (35, 49) 49 (22, 50) 1.00 (0.55, 1.82) 0.99 
TaqI VDR genotype       
TT 394 (3) 36 (22, 50) 35 (22, 50) 1.10 (0.88, 1.38) 0.41 
0.95 Tt 162 (3)  36 (21, 49) 35 (21, 52) 0.96 (0.68, 1.37) 0.83 
tt 42 (3) 35 (22, 53) 34 (9, 40) 1.54 (0.77, 3.08) 0.22 
 
1, adjusted for age, sex and clustering within trials, except for sub-group analysis by age (where age was not adjusted for) and sex (where sex 
was not adjusted for) 2, isolate resistant to both isoniazid and rifampicin, at least. 3, survival times were truncated at 56 days in order to capture 
effects of adjunctive vitamin D on the standardized background of intensive-phase antimicrobial therapy; values for time to sputum culture 
conversion of greater than 56 days are therefore marked ‘>56’. 4, the P value for interaction for this sub-group analysis remained significant 
after correction for multiple comparisons testing, using the Benjamini and Hochberg method with a false discovery rate of 20%. 5, within-
subgroup adjusted hazard ratio and P value could not be calculated due to non-convergence of model. 
 




Figure 2: Time to sputum culture and smear conversion by allocation: one-step individual participant data meta-
analysis. A, time to sputum culture conversion by allocation. B, time to sputum smear conversion by allocation. Numbers 
of participants with positive sputum culture or smear remaining in follow-up (number at risk) at 0, 14, 28, 42, and 56 days 
are shown. Adjusted hazard ratios (aHR) with 95% confidence intervals (CI) are from mixed models with a random effect 
for study and fixed effects for age and sex.






















































































Figure 3: Time to sputum culture conversion by allocation: two-step individual participant data meta-analysis. 














Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual 






Cochrane Highly Sensitive Search Strategy for identifying randomized controlled 
trials  
 
#1. randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] 
OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups 
[tiab] 
#2. animals [mh] NOT humans [mh] 
#3. #1 NOT #2 
 
Terms specific to vitamin D 
 
#4. Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR 
alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol 
 




Combination of terms to identify randomized controlled trials of vitamin D 
conducted in patients with tuberculosis 
 




Terms for identifying randomized controlled trials 
 
#1 ‘randomized controlled trial’/exp OR ‘single blind procedure’/exp OR ‘double blind 
procedure’/exp OR ’crossover procedure’/exp 
#2 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR 
allocat*:ab,ti OR ((singl* OR doubl*) NEXT/1 blind*):ab,ti OR trial:ti 






Terms specific to vitamin D 
 
#4. vitamin AND d OR vitamin AND d2 OR vitamin AND d3 OR cholecalciferol OR 








Combination of terms to identify randomized controlled trials of vitamin D 
conducted in patients with tuberculosis 
 
#3 AND #4 AND #5 
 
C. Cochrane Central 
 
Terms specific to vitamin D 
 
#1. Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR 
alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol 
 




Combination of terms to identify randomized controlled trials of vitamin D 
conducted in patients with tuberculosis 
 
#1 AND #2 
 
D. Web of Science 
 
TS =(Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR 
alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol) AND TS 
=(Tuberculosis) AND TS =(placebo* or random* or clinical trial* or double blind* or 






Appendix Table 1: Final treatment outcome by study and allocation1 
 
 Ralph et al
1
 Wejse et al
2
 
 Placebo (n) Vitamin D (n) Placebo (n) Vitamin D (n) 
Cured 32 36 59 72 
Completed 6 4 34 29 
Failed 1 0 0 0 
Defaulted 0 5 14 9 
Died 0 2 9 12 
Transferred 2 2 1 2 
Total 41 49 117 124 




Appendix Table 2: Baseline characteristics by allocation: all analyzed participants (n=1,850) 
 
 Placebo group (n=923) Vitamin D group (n=927) 
Mean baseline 25(OH)D concentration, nmol/L (SD)
1
 41.0 (35.7) 41.3 (33.6) 
Baseline 25(OH)D concentration (%)
1
   
<25 nmol/L 359 (38.9) 329 (35.4) 
≥25 nmol/L 478 (51.8) 494 (53.3) 
Mean age, years (SD)  34.0 (13.8) 33.0 (13.0) 
Age (%)   
<30 years  450 (48.8) 467 (50.4) 
≥30 years 473 (51.2) 460 (49.6) 
Sex (%)   
Male 611 (66.2) 589 (63.5) 
Female 312 (33.8) 338 (36.5) 
Mean weight, kg (SD)
2
 51.2 (11.3) 51.0 (10.9) 
Multidrug resistance (%)
3
   
No 619 (67.1) 600 (64.7) 
Yes 25 (2.7) 30 (3.2) 
HIV status
4
   
Seronegative 507 (54.9) 492 (53.1) 
Seropositive 41 (4.4) 68 (7.3) 
% zones involved, baseline CXR (%)
5
   
<50% 362 (39.2) 359 (38.7) 
≥50% 146 (15.8) 137 (14.8) 
Cavitation, baseline CXR (%)
6
    
No 330 (35.8) 341 (36.8) 
Yes 334 (36.2) 324 (35.0) 
Vitamin D Dosing Regimen (%)   
Daily/weekly 223 (24.2) 229 (24.7) 
Bolus/2-weekly 700 (75.8) 698 (75.3) 
FokI VDR genotype (%)
7
   
FF 183 (19.8) 194 (20.9) 
Ff 150 (16.3) 149 (16.1) 
ff 36 (3.9) 20 (2.2) 
TaqI VDR genotype (%)
8
   
TT 258 (28.0) 245 (26.4) 
Tt 140 (15.2) 140 (15.1) 
tt 29 (3.1) 32 (3.5) 
25(OH)D, 25-hydroxyvitamin D; CXR, chest radiograph; SD, standard deviation; HIV, human immunodeficiency virus; VDR, vitamin D 
receptor. 
 
1. Data available for n=837 in the placebo group and n=823 in the vitamin D group; 2. Data available for n=906 in the placebo group 
and n=914 in the vitamin D group; 3. Data available for n=644 in the placebo group and n=630 in the vitamin D group; multidrug 
resistance defined as being resistant to both isoniazid and rifampicin, at least; 4. Data available for n=548 in the placebo group and 
n=560 in the vitamin D group; 5. Data available for n=408 in the placebo group and n=496 in the vitamin D group; 6. Data available for 
n=664 in the placebo group and n=665 in the vitamin D group; 7. Data available for n=369 in the placebo group and n=363 in the 
vitamin D group; 8. Data available for n=427 in the placebo group and n=417 in the vitamin D group. 
 
Appendix Table 3: Baseline characteristics by allocation: participants with multidrug-
resistant tuberculosis (n=55)(1) 
 
  Placebo group (n=25) Vitamin D group (n=30) 
Mean age, years (SD)  30.7 (7.8) 31.8 (13.1) 
Age (%) <30 years  13 (52.0) 19 (63.3) 
 ≥30 years 12 (48.0) 11 (36.7)  
Sex (%) Male 15 (60.0) 16 (53.3) 
Male Female 10 (40.0) 14 (46.7) 
Mean baseline 25(OH)D concentration, nmol/L (SD)
(2)





<25 nmol/L 17 (68.0) 17 (56.7) 
 ≥25 nmol/L 7 (28.0) 12 (40.0) 
 Not known 1 (4.0) 1 (3.3) 
Mean weight, kg (SD) 54.1 (11.1) 55.5 (9.7) 
HIV status 
(%) 
Seronegative 11 (44.0) 13 (43.3) 
 Seropositive 0 (0.0) 1 (3.3) 




No 13 (52.0) 21 (70.0) 
 Yes 12 (48.0) 8 (26.7) 




Daily/weekly 15 (60.0) 15 (50.0) 




Phenylbutyrate 3 (12.0) 1 (3.3) 
 L-arginine 1 (4.0) 0 (0.0) 






FF 2 (8.0) 6 (20.0) 
 Ff 5 (20.0) 6 (20.0) 
 ff 2 (8.0) 1 (3.3) 






TT 9 (36.0) 13 (43.3) 
 Tt 3 (12.0) 1 (3.3) 
 tt 4 (16.0) 1 (3.3) 
 Not known 9 (36.0) 15 (50.0) 
Antimicrobia
l sensitivity 
Resistant to isoniazid and rifampicin only 10 (40.0) 15 (50.0) 
 




15 (60.0) 15 (50.0) 
25(OH)D, 25-hydroxyvitamin D; CXR, chest radiograph; SD, standard deviation; HIV, human immunodeficiency 
virus; VDR, vitamin D receptor. 
 
1. Multidrug-resistant tuberculosis defined as resistance of isolate to both isoniazid and rifampicin, at least. 
2. Baseline 25(OH)D concentration missing for 1 participant in the placebo group and 1 participant in the vitamin D 
group 
3. Isolates additionally resistant to ethambutol, streptomycin or both 
 
  





































































































































     ?
1   
Martineau 2011 
3
        
Salahuddin 2013 
4
        
Ralph 2013 
1
     ?
1   
Mily 2015 
5
     ?
1   
Daley 2015 
6
     ?
1   
Tukvadze 2015 
7
        
Ganmaa 2017 
8
        
 
 = low risk of bias; ? = unclear risk of bias; 
1, risk of bias due to incomplete outcome data assessed as ‘unclear’ due to relatively high rates of loss to follow-up (>20%) 
 
Appendix Table 5: One-step individual participant data meta-analysis, safety outcomes 
 
  N 
participants 
(trials) 
Proportion with ≥1 
event, placebo 
group (%) 
Proportion with ≥1 
event, vitamin D 
group (%) 







 6 39/639 (6.1) 38/614 (6.2) 0.94 (0.55, 1.62) 0.83 
Renal stones 8 0/923 (0.0) 0/927 (0.0) -- -- 
Serious Adverse Events, 
any cause 
8 32/923(3.5) 33/927 (3.6) 0.99 (0.59, 1.65) 0.96 
Withdrawals/loss to follow-
up 
8 124/923 (13.4) 117/927 (12.6) 0.96 (0.73, 1.27) 0.79 
Total Deaths 8 21/923 (2.3) 23/927 (2.5) 1.09 (0.59, 2.03) 0.79 
1, adjusted for age, sex and clustering between trials 
2, hypercalcemia defined as serum calcium concentration >2.65 mmol/L; serum calcium concentration was corrected for serum 
albumin concentration where this was also measured (4/6 studies). In all studies where serum calcium concentrations were 
measured, this was done routinely i.e. irrespective of symptoms 
 
 
Appendix Table 6: One-step individual participant data meta-analysis, responder 
analysis 
 
  N 
participants 
(N trials) 
Median time to sputum culture 
conversion, days (IQR) 
Adjusted hazard ratio 
(95% CI) 
P value 
Intervention, end-study 25(OH)D 
< 75 nmol/L 
34 (3) 28 (28, 56) Referent  
Intervention, end-study 25(OH)D 
≥ 75 nmol/L 
232 (4) 28 (28, 53) 0.95 (0.63, 1.41) 0.78 
Appendix Figure 1: Funnel plot for individual patient data meta-analysis of time to 
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